What is HC Wainwright's Estimate for enGene Q1 Earnings?

Key Points

• HC Wainwright has projected enGene Holdings Inc. to report a Q1 2026 earnings per share of ($0.64), with a current full-year earnings estimate of ($1.56) per share.
• The stock has a current Buy rating from HC Wainwright and a target price of $25.00, while Morgan Stanley has lowered its price objective from $19.00 to $18.00.
• enGene's shares opened at $5.71, reflecting a recent decline of 5.8% and an overall market cap of approximately $291.78 million.

enGene Holdings Inc. (NASDAQ:ENGN - Free Report) - Research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for enGene in a research report issued to clients and investors on Friday, September 12th. HC Wainwright analyst A. Maldonado expects that the company will earn ($0.64) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $25.00 target price on the stock. The consensus estimate for enGene's current full-year earnings is ($1.56) per share. HC Wainwright also issued estimates for enGene's Q2 2026 earnings at ($0.59) EPS and Q3 2026 earnings at ($0.63) EPS.

enGene (NASDAQ:ENGN - Get Free Report) last announced its quarterly earnings data on Thursday, September 11th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.06).

Separately, Morgan Stanley decreased their price objective on enGene from $19.00 to $18.00 and set an "overweight" rating on the stock in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $21.00.

enGene Stock Down 5.8%

Shares of NASDAQ ENGN opened at $5.71 on Monday. The company has a market cap of $291.78 million, a P/E ratio of -3.01 and a beta of -0.40. The company has a quick ratio of 10.34, a current ratio of 10.34 and a debt-to-equity ratio of 0.09. The business has a 50-day simple moving average of $4.12 and a two-hundred day simple moving average of $4.11. enGene has a 52 week low of $2.65 and a 52 week high of $11.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ENGN. VR Adviser LLC lifted its holdings in shares of enGene by 41.5% during the fourth quarter. VR Adviser LLC now owns 5,046,414 shares of the company's stock valued at $33,559,000 after purchasing an additional 1,480,573 shares in the last quarter. Point72 Asset Management L.P. increased its position in enGene by 84.7% during the fourth quarter. Point72 Asset Management L.P. now owns 1,224,797 shares of the company's stock valued at $8,145,000 after acquiring an additional 561,797 shares during the last quarter. Vestal Point Capital LP purchased a new stake in enGene during the fourth quarter valued at $2,460,000. Affinity Asset Advisors LLC purchased a new stake in enGene during the second quarter valued at $280,000. Finally, Adage Capital Partners GP L.L.C. increased its position in enGene by 2.7% during the first quarter. Adage Capital Partners GP L.L.C. now owns 1,571,642 shares of the company's stock valued at $7,041,000 after acquiring an additional 41,874 shares during the last quarter. 64.16% of the stock is owned by institutional investors.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.